Cargando…
Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1
Oncolytic type-1 herpes simplex viruses (oHSVs) lacking the γ(1)34.5 neurovirulence gene are being evaluated for treatment of a variety of malignancies. oHSVs replicate within and directly kill permissive cancer cells. To augment their anti-tumor activity, oHSVs have been engineered to express immun...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842420/ https://www.ncbi.nlm.nih.gov/pubmed/24312353 http://dx.doi.org/10.1371/journal.pone.0081768 |
_version_ | 1782292928154042368 |
---|---|
author | Gaston, David C. Odom, Carl I. Li, Li Markert, James M. Roth, Justin C. Cassady, Kevin A. Whitley, Richard J. Parker, Jacqueline N. |
author_facet | Gaston, David C. Odom, Carl I. Li, Li Markert, James M. Roth, Justin C. Cassady, Kevin A. Whitley, Richard J. Parker, Jacqueline N. |
author_sort | Gaston, David C. |
collection | PubMed |
description | Oncolytic type-1 herpes simplex viruses (oHSVs) lacking the γ(1)34.5 neurovirulence gene are being evaluated for treatment of a variety of malignancies. oHSVs replicate within and directly kill permissive cancer cells. To augment their anti-tumor activity, oHSVs have been engineered to express immunostimulatory molecules, including cytokines, to elicit tumor-specific immune responses. Interleukin-15 (IL-15) holds potential as an immunotherapeutic cytokine because it has been demonstrated to promote both natural killer (NK) cell-mediated and CD8(+) T cell-mediated cytotoxicity against cancer cells. The purpose of these studies was to engineer an oHSV producing bioactive IL-15. Two oHSVs were constructed encoding murine (m)IL-15 alone (J100) or with the mIL-15 receptor α (mIL-15Rα, J100D) to determine whether co-expression of these proteins is required for production of bioactive mIL-15 from oHSV. The following were demonstrated: i) both oHSVs retain replication competence and cytotoxicity in permissive tumor cell lines. ii) Enhanced production of mIL-15 was detected in cell lysates of neuro-2a cells following J100D infection as compared to J100 infection, suggesting that mIL-15Rα improved mIL-15 production. iii) Soluble mIL-15 in complex with mIL-15Rα was detected in supernates from J100D-infected, but not J100-infected, neuro-2a, GL261, and CT-2A cells. These cell lines vary in permissiveness to oHSV replication and cytotoxicity, demonstrating soluble mIL-15/IL-15Rα complex production from J100D was independent of direct oHSV effects. iv) The soluble mIL-15/IL-15Rα complex produced by J100D was bioactive, stimulating NK cells to proliferate and reduce the viability of syngeneic GL261 and CT-2A cells. v) J100 and J100D were aneurovirulent inasmuch as no neuropathologic effects were documented following direct inoculation into brains of CBA/J mice at up to 1x10(7) plaque forming units. The production of mIL-15/mIL-15Rα from multiple tumor lines, as well as the lack of neurovirulence, renders J100D suitable for investigating the combined effects of oHSV and mIL-15/IL-15Rα in various cancer models. |
format | Online Article Text |
id | pubmed-3842420 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38424202013-12-05 Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 Gaston, David C. Odom, Carl I. Li, Li Markert, James M. Roth, Justin C. Cassady, Kevin A. Whitley, Richard J. Parker, Jacqueline N. PLoS One Research Article Oncolytic type-1 herpes simplex viruses (oHSVs) lacking the γ(1)34.5 neurovirulence gene are being evaluated for treatment of a variety of malignancies. oHSVs replicate within and directly kill permissive cancer cells. To augment their anti-tumor activity, oHSVs have been engineered to express immunostimulatory molecules, including cytokines, to elicit tumor-specific immune responses. Interleukin-15 (IL-15) holds potential as an immunotherapeutic cytokine because it has been demonstrated to promote both natural killer (NK) cell-mediated and CD8(+) T cell-mediated cytotoxicity against cancer cells. The purpose of these studies was to engineer an oHSV producing bioactive IL-15. Two oHSVs were constructed encoding murine (m)IL-15 alone (J100) or with the mIL-15 receptor α (mIL-15Rα, J100D) to determine whether co-expression of these proteins is required for production of bioactive mIL-15 from oHSV. The following were demonstrated: i) both oHSVs retain replication competence and cytotoxicity in permissive tumor cell lines. ii) Enhanced production of mIL-15 was detected in cell lysates of neuro-2a cells following J100D infection as compared to J100 infection, suggesting that mIL-15Rα improved mIL-15 production. iii) Soluble mIL-15 in complex with mIL-15Rα was detected in supernates from J100D-infected, but not J100-infected, neuro-2a, GL261, and CT-2A cells. These cell lines vary in permissiveness to oHSV replication and cytotoxicity, demonstrating soluble mIL-15/IL-15Rα complex production from J100D was independent of direct oHSV effects. iv) The soluble mIL-15/IL-15Rα complex produced by J100D was bioactive, stimulating NK cells to proliferate and reduce the viability of syngeneic GL261 and CT-2A cells. v) J100 and J100D were aneurovirulent inasmuch as no neuropathologic effects were documented following direct inoculation into brains of CBA/J mice at up to 1x10(7) plaque forming units. The production of mIL-15/mIL-15Rα from multiple tumor lines, as well as the lack of neurovirulence, renders J100D suitable for investigating the combined effects of oHSV and mIL-15/IL-15Rα in various cancer models. Public Library of Science 2013-11-27 /pmc/articles/PMC3842420/ /pubmed/24312353 http://dx.doi.org/10.1371/journal.pone.0081768 Text en © 2013 Gaston et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Gaston, David C. Odom, Carl I. Li, Li Markert, James M. Roth, Justin C. Cassady, Kevin A. Whitley, Richard J. Parker, Jacqueline N. Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 |
title | Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 |
title_full | Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 |
title_fullStr | Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 |
title_full_unstemmed | Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 |
title_short | Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1 |
title_sort | production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic hsv-1 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842420/ https://www.ncbi.nlm.nih.gov/pubmed/24312353 http://dx.doi.org/10.1371/journal.pone.0081768 |
work_keys_str_mv | AT gastondavidc productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT odomcarli productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT lili productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT markertjamesm productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT rothjustinc productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT cassadykevina productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT whitleyrichardj productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 AT parkerjacquelinen productionofbioactivesolubleinterleukin15incomplexwithinterleukin15receptoralphafromaconditionallyreplicatingoncolytichsv1 |